DGAP-News

MOLOGEN AG successfully completes capital increase - Seite 2

for completing patient enrolment for the pivotal study with MGN1703 in the
indication of colorectal cancer (IMPALA) is 2016.

quirin bank AG, Berlin, was the sole bookrunner for the transaction.

Important note:
This announcement does not contain or constitute an offer of, or the
solicitation of an offer to buy or subscribe for, securities.

This release does not constitute an offer of securities for sale in the
United States of America. In the United States of America, no securities
may be offered or sold absent registration or in exercise of an exemption
from registration under the U.S. Securities Act of 1933, as amended (the
"Securities Act"). There will be no public offer of the securities in the
United States of America. Subject to certain exceptions, the securities
referred to herein may not be offered or sold in Australia, Canada, Japan
or South Africa or to, or for the account or benefit of, any national,
resident or citizen of Australia, Canada, Japan or South Africa.

This document is not for general publication, release or distribution in
the United Kingdom and may only be distributed in the United Kingdom to
persons who (i) are investment professionals falling within article 19(5)
of the U.K. Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005, in its current version (the "Order"), or (ii) are high net
worth entities or other persons to whom it may lawfully be communicated
within the meaning of article 49(2)(a) to (d) of the Order (each such
person a "Relevant Person"). Anyone in the United Kingdom who is not a
Relevant Person may not act on the basis of this document or its contents
or rely thereon. Any investment or investment activity to which this
document refers is only available to a Relevant Person and is only carried
out with a Relevant Person.

MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immunotherapies and DNA vaccines against
infectious diseases.

The cancer immune therapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and
lung cancer (randomized controlled trial). A second clinical-stage product
is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A
phase I/II clinical study has already been completed successfully.

For more information on the trials please visit: www.clinicaltrials.gov.